Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM378995 (Preparation of {3-[({2-[1-(4-ethoxy-2,6-difluorobe...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.40 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM378915 (2-[1-(6-chloro-2-fluoro-3-methylbenzyl)-1H-indazol...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.60 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM378932 (2-[1-(6-chloro-2- fluoro-3- methoxybenzyl)- 1H-ind...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.60 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379026 (Preparation of 1-[3,5-difluoro-4-({3-[5-methoxy-4-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379042 (Preparation of 2-({2-[1-(4-ethoxy-2,6-difluorobenz...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.30 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379006 (US10266548, Example 4-2-1 | {3[({2-[1-(2- fluorobe...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.30 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379108 (2-[1-(4-ethoxy-2,6- difluorobenzyl)-1H- indazol-3-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.40 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379107 (Preparation of 5-(2-aminoethoxy)-2-[1-(4-ethoxy-2,...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.40 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379024 (Preparation of 2-[1-(4-cyclopropyl-2,6-difluoroben...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.90 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM378946 (2-[1-(2-chloro- 4,5- dimethylbenzyl)- 1H-indazol-3...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.40 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM378960 (2-[1-(2,6- difluoro-3- methoxybenzyl)- 1H-indazol-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.5 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379040 (Preparation of (2R)-3-({2-[1-(2-fluorobenzyl)-1H-i...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.60 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM378973 (2-[1-(4-ethoxy- 2,6- difluorobenzyl)- 1H-indazol-3...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.60 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379040 (Preparation of (2R)-3-({2-[1-(2-fluorobenzyl)-1H-i...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.60 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM378980 (2-[1-(2-chloro-4- methoxybenzyl)- 1H-indazol-3-yl]...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.70 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379045 (4-({2-[1-(2- fluorobenzyl)- 1H-indazol-3-yl]- 5-(2...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.70 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM378991 (Preparation of 2-[1-(4-ethoxy-2,6-difluorobenzyl)-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.70 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM378982 (2-[1-(2,6- difluorobenzyl)- 1H-indazol-3-yl]- 5-me...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.80 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379041 ((2S)-3-({2-[1-(2- fluorobenzyl)- 1H-indazol-3-yl]-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | KEGG PC cid PC sid UniChem | US Patent | n/a | n/a | 4.80 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379103 (Preparation of 2-[1-(4-ethoxy-2,6-difluorobenzyl)-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.91 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379085 (4-({2-[1-(2,6- difluoro-4- hydroxybenzyl)-1H- inda...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.03 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379021 (Preparation of 2-[1-(4-ethoxy-2,6-difluorobenzyl)-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.20 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379049 (Preparation of 2-[1-(4-ethoxy-2,6-difluorobenzyl)-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.20 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379083 (4-({5-methoxy-2-[1- (4-propylbenzyl)- 1H-indazol-3...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.40 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379019 (1-({2-[1-(4- ethoxy-2,6- difluorobenzyl)- 1H-indaz...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.40 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM378971 (2-[1-(2,6- difluoro-3- methylbenzyl)- 1H-indazol-3...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.5 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379041 ((2S)-3-({2-[1-(2- fluorobenzyl)- 1H-indazol-3-yl]-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | KEGG PC cid PC sid UniChem | US Patent | n/a | n/a | 5.5 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM378958 (2-{1-[4- (difluoro- methoxy)-2,6- difluorobenzyl]-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.60 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379106 (Preparation of 2-[1-(4-ethoxy-2,6-difluorobenzyl)-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.70 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379042 (Preparation of 2-({2-[1-(4-ethoxy-2,6-difluorobenz...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.70 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379004 (US10266548, Example 4-18 | US10266548, Example 4-2...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.80 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379004 (US10266548, Example 4-18 | US10266548, Example 4-2...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.80 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379103 (Preparation of 2-[1-(4-ethoxy-2,6-difluorobenzyl)-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 6.20 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379103 (Preparation of 2-[1-(4-ethoxy-2,6-difluorobenzyl)-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 6.30 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379064 (({2-[1-(4-ethoxy- 2,6- difluorobenzyl)- 1H-indazol...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 6.30 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379046 (4-({2-[1-(2- fluorobenzyl)- 1H-indazol-3-yl]- 5-(2...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 6.5 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM378917 (2-[1-(2- chlorobenzyl)- 1H-indazol-3-yl]- 5-methox...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 6.70 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM378985 (2-[1-(2,3- difluoro-4- methylbenzyl)- 1H-indazol-3...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 6.70 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM378988 (2-[1-(2,6- dichlorobenzyl)- 1H-indazol-3-yl]- 5-me...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 6.70 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379112 (Preparation of 2-[1-(4-ethoxy-2,6-difluorobenzyl)-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 6.70 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM378919 (US10266548, Example 2-11-1 | methyl 3-chloro- 4-({...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 7.10 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379043 (2-({2-[1-(2- fluorobenzyl)- 1H-indazol-3-yl]- 4-(p...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 7.20 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM378921 (2-[1-(4-bromo- 2,6- difluorobenzyl)- 1H-indazol-3-...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 7.30 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM378988 (2-[1-(2,6- dichlorobenzyl)- 1H-indazol-3-yl]- 5-me...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 7.30 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379027 (Preparation of [2,4-dichloro-3-({3-[5-methoxy-4-(p...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 7.40 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379003 (2-[2-({2-[1-(4- ethoxy-2,6- difluorobenzyl)- 1H-in...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 7.40 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379025 (2-(1-{2,6-difluoro- 4-[(1E)-prop-1-en- 1-yl]benzyl...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 7.40 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379003 (2-[2-({2-[1-(4- ethoxy-2,6- difluorobenzyl)- 1H-in...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 7.40 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM379008 (US10266548, Example 4-3) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 7.5 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Mitotic checkpoint serine/threonine-protein kinase BUB1 (Homo sapiens (Human)) | BDBM378999 (2-[1-(2- fluorobenzyl)- 1H-indazol-3-yl]- 5-{[3- (...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 7.60 | n/a | n/a | n/a | n/a | n/a | n/a |
Johnson & Johnson Pharmaceutical | Assay Description Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE... | J Med Chem 51: 4150-69 (2008) BindingDB Entry DOI: 10.7270/Q2RV0R1M | |||||||||||
More data for this Ligand-Target Pair |
Displayed 1 to 50 (of 211 total ) | Next | Last >> |